The total return over the past 12 months is +13.22% vs. +16.94% for the S&P 500. So far it's up +3.85% this year. Includes price appreciation + reinvested dividends.
| Category | 1Y (TTM) | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Price CAGR | +13.22% | +6.90% | (10.02%) | +5.82% | +7.60% | (1.64%) |
| Total Return CAGR | +13.22% | +6.90% | (10.02%) | +5.82% | +7.60% | (1.64%) |
| Revenue CAGR | +68.72% | +45.29% | +64.07% | +43.62% | +23.88% | +34.84% |
| Net Income CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
| EPS CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
| Free Cash Flow CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
| Operating Cash Flow CAGR | N/A | N/A | N/A | N/A | N/A | +35.88% |
| Dividends CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
Visualize historical growth rates over rolling horizons. Use the dropdown to select different metric vectors.
BioCryst Pharmaceuticals, Inc. (BCRX)
| Year | Start price | End price | BCRX Return | SPY Return | Outperformance |
|---|---|---|---|---|---|
| 2026(YTD) | $7.80 | $8.10 | +3.85% | +14.51% | (10.66%) |
| 2025 | $7.52 | $7.80 | +3.72% | +17.72% | (14.00%) |
| 2024 | $5.99 | $7.52 | +25.54% | +24.89% | +0.65% |
| 2023 | $11.48 | $5.99 | (47.82%) | +26.19% | (74.01%) |
| 2022 | $13.85 | $11.48 | (17.11%) | (18.17%) | +1.06% |
| 2021 | $7.45 | $13.85 | +85.91% | +28.74% | +57.17% |
| 2020 | $3.45 | $7.45 | +115.94% | +18.37% | +97.57% |
| 2019 | $8.07 | $3.45 | (57.25%) | +31.22% | (88.47%) |
| 2018 | $4.91 | $8.07 | +64.36% | (4.56%) | +68.92% |
| 2017 | $6.33 | $4.91 | (22.43%) | +21.70% | (44.13%) |
Start and end prices are split-adjusted closing prices. Total return includes reinvested dividends, so it can differ from the price change.
